Soligenix Inc. SNGX Archives

FridayMar 20, 2026 11:15 am

Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation

Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs. The UK Medicines and Healthcare Products Regulatory Agency granted Promising Innovative Medicine designation to Soligenix’s SGX945 (dusquetide) for the treatment of Behçet’s disease. The recent designation in the United Kingdom builds on other regulatory recognitions previously granted to dusquetide. Regulatory recognition from international health authorities can significantly shape the trajectory of emerging therapies worldwide, particularly in rare disease development where clinical pathways are often complex and resource intensive. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases and…

WednesdayMar 18, 2026 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline

High-quality development platforms and translational research frameworks have become essential tools in rare-disease biotechnology. Soligenix is leveraging its platform science to expand the therapeutic reach of its development programs and explore additional disease indications. The broader emphasis of Soligenix’s platform science approach is to maximize the scientific value of its research infrastructure. Medical progress has transformed the treatment of many common illnesses, yet thousands of rare diseases still lack effective therapies. Companies working at the intersection of biotechnology innovation and rare disease research are increasingly focused on addressing these gaps, including Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing and…

TuesdayMar 10, 2026 9:00 am

QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease

Soligenix (NASDAQ: SNGX) announced that SGX945 (dusquetide) has received Promising Innovative Medicine (“PIM”) designation from the U.K. Medicines and Healthcare Products Regulatory Agency for the treatment of Behçet’s Disease. The designation represents the first step toward potential inclusion in the U.K.’s Early Access to Medicines Scheme, which allows patients with life-threatening or seriously debilitating conditions to access promising therapies earlier. The PIM designation was granted based on Phase 2 clinical data indicating that dusquetide may provide a significant advantage over existing treatments while demonstrating a favorable potential benefit-risk profile for patients with this rare inflammatory disorder. To view the full…

MondayMar 09, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Secures Key European Milestone for Dusquetide Development

“The EMA's positive opinion signifies an important step for Soligenix as we continue to advance the program,” says company CEO. The designation provides incentives that may include protocol assistance, reduced regulatory fees and up to 10 years of market exclusivity following approval. Dusquetide is classified as an innate defense regulator, a type of compound designed to modulate the body’s innate immune system rather than suppress it outright. For patients living with rare inflammatory diseases, regulatory milestones can mark the difference between stalled research and meaningful therapeutic progress. A positive opinion from the European Medicines Agency (EMA) not only validates a…

ThursdayMar 05, 2026 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach

Platform-based drug development has gained traction across the biotechnology industry because of its efficiency and risk management advantages. Soligenix’s development of synthetic hypericin illustrates this “one drug, multiple diseases” model in action. HyBryte is being developed to treat both cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin, and psoriasis. Modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism can unlock treatments for multiple diseases. Rather than building entirely new molecules for every indication, companies are developing platform technologies that allow a single therapeutic approach to be adapted across conditions. Soligenix…

TuesdayFeb 24, 2026 9:20 am

QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit

Soligenix (NASDAQ: SNGX) announced that Christopher J. Schaber, Ph.D., president and chief executive officer, will deliver a corporate presentation at the BIO Investment & Growth Summit at 3 p.m. on March 2. The conference, scheduled for March 2-3 at Eden Roc Miami Beach in Miami Beach, Florida, will feature company presentations, one-on-one meetings and programming focused on growth-stage biotechnology companies. Additional information is available on the conference website. To view the full press release, visit https://ibn.fm/sOzzL About Soligenix Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical…

TuesdayFeb 10, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology

One of the key advantages of photodynamic therapy is its selectivity. Soligenix is advancing HyBryte(TM), or SGX301, designed for the treatment of cutaneous T-cell lymphoma. The company has achieved an important safety milestone in its confirmatory phase 3 clinical trial of HyBryte for CTCL treatment. From lab research to clinical application, photodynamic therapy (“PDT”) is emerging as a powerful treatment approach that uses light and chemistry to selectively target diseased tissue. As this modality gains attention for its precision and safety profile, Soligenix (NASDAQ: SNGX) is developing light-activated therapies designed to treat cutaneous T-cell lymphoma (“CTCL”) and other inflammatory skin…

MondayFeb 02, 2026 12:00 pm

Soligenix Inc. (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer

Although CTCL may progress slowly in its early stages, it remains a chronic and ultimately progressive disease for many patients. Front-line therapies for CTCL remain limited and fragmented. Soligenix is advancing a distinct approach to CTCL treatment through the development of HyBryte(TM), also known as SGX301 or synthetic hypericin. Cutaneous T-cell lymphoma (“CTCL”) remains a cancer with limited treatment options, persistent symptoms and long-term quality-of-life challenges for patients, even decades after its classification as a distinct disease. Despite medical advances in oncology, many people living with CTCL continue to cycle through therapies that offer only partial relief or introduce new…

FridayJan 30, 2026 10:30 am

Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape

The World Health Organization’s recent recognition of rare diseases as a global health priority underscores their collective impact. Soligenix remains focused on delivering meaningful progress in rare disease-based therapeutics and public health. In its Specialized Biotherapeutics segment, Soligenix is advancing candidates designed for orphan diseases and other serious conditions where treatment options are limited. As the global burden of rare diseases continues to rise, there is increasing urgency for innovative therapies that address unmet medical needs. More than 300 million people worldwide live with one or more rare diseases, many of which have limited or no approved treatment options, and…

FridayJan 16, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Announces Positive Phase 2 Data for Rare Inflammatory Disease

Behçet’s disease is characterized by unpredictable flare-ups and periods of remission, making long-term management particularly challenging. Current treatment strategies for the disease focus on controlling inflammation and suppressing immune activity using corticosteroids, immunosuppressants and biologic agents. Soligenix has released positive top-line results from its phase 2 clinical trial evaluating SGX945 for the treatment of aphthous ulcers associated with Behçet’s. Behçet’s disease is a rare, chronic inflammatory condition that can cause recurrent, painful ulcers, eye inflammation and systemic complications that significantly affect quality of life. Because available treatments are limited and often inconsistent, clinical trial updates in this disease area carry…

Site Search

Company Search

Tag: Soligenix Inc. SNGX